Table 3.
Change in neurodevelopmental outcome from 18 to 36 months: change over time associated with timing of triptan exposure, within migraine-only sample (N=5484)
| Per cent (8 months)† | Per cent (36 months) | Unadjusted |
MSM* |
|||
|---|---|---|---|---|---|---|
| r-RR‡ | 95% CI | r-RR | 95% CI | |||
| CBCL externalising behaviour | ||||||
| Prepregnancy | 8.4 | 7.5 | 0.94 | 0.67 to 1.30 | 0.90 | 0.64 to 1.25 |
| First trimester | 11.6 | 11.1 | 1.16 | 0.73 to 1.86 | 1.01 | 0.56 to 1.80 |
| Second/third trimester | 10.7 | 9.8 | 0.96 | 0.48 to 1.91 | 0.50 | 0.17 to 1.48 |
| EAS emotionality | ||||||
| Prepregnancy | 4.7 | 4.7 | 1.07 | 0.69 to 1.67 | 1.07 | 0.68 to 1.67 |
| First trimester | 3.8 | 5.6 | 1.43 | 0.58 to 3.51 | 1.54 | 0.57 to 4.13 |
| Second/third trimester | 4.0 | 7.1 | 1.52 | 0.48 to 4.85 | 2.41 | 0.71 to 8.20 |
| EAS activity | ||||||
| Prepregnancy | 9.6 | 5.7 | 0.90 | 0.63 to 1.28 | 0.88 | 0.61 to 1.28 |
| First trimester | 9.3 | 8.9 | 1.56 | 0.90 to 2.71 | 1.98 | 0.90 to 4.34 |
| Second/third trimester | 9.4 | 10.7 | 1.56 | 0.76 to 3.21 | 1.37 | 0.46 to 4.10 |
*Per cent is the per cent with outcome at each measurement (18 and 36 months postpartum), among those with exposure at each time point (eg, per cent with externalising problems at 18 months with prenatal triptan use={(75/1002)×100}=7.49%. Windows of triptan exposure are not mutually exclusive).
†r-RR is the group-by-time interaction coefficient from the generalised estimating equation model; it is the difference in change from 18 to 36 months for each group, relative to no exposure during that time point.
‡Models are weighted by the product of stabilised IPCW and IPTW; IPCW is the probability of dropout, conditional on maternal age, prepregnancy BMI, marital status, parity, migraine history and use of triptans prior to and during pregnancy. IPTW includes baseline covariates (maternal age, prepregnancy BMI, sociodemographic variables), time-invariant predictors (smoking and alcohol use during pregnancy, folate supplementation, maternal depression severity), time-varying concomitant medication use (acetaminophen, NSAIDs, opioids, antidepressants) and treatment history (triptan use).
BMI, body mass index; CBCL, Child Behaviour Checklist; EAS, Emotionality, Activity and Shyness Temperament Questionnaire; IPCW, inverse probability of censoring weight; IPTW, inverse probability of treatment weight; MSM, marginal structural models; r-RR, ratio of risk ratios.